Double-blind, placebo-controlled, single and multiple ascending dose phase I trial evaluating the safety, tolerability and pharmacokinetics of CCX 872 in volunteers
Phase of Trial: Phase I
Latest Information Update: 22 Apr 2015
At a glance
- Drugs CCX 872 (Primary)
- Indications Kidney disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors ChemoCentryx
- 20 Apr 2015 According to ChemoCentryx media release, results will be presented at the American Association for Cancer Research (AACR).
- 12 Mar 2015 Status changed from active, no longer recruiting to completed, according to a ChemoCentryx media release.
- 23 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.